Hyponatremia in heart failure: The role of arginine vasopressin and diuretics

Cardiovascular Drugs and Therapy

Volumn 23, Issue 4, 2009, Pages 307-315

  Rosner, Mitchell H ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Aquaresis; Congestive heart failure; Diuretics; Vasopressin

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ARGIPRESSIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CONIVAPTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; LIXIVAPTAN; LOOP DIURETIC AGENT; MILRINONE; PLACEBO; SODIUM ION; THIAZIDE DIURETIC AGENT; TOLVAPTAN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V1B RECEPTOR; VASOPRESSIN V2 RECEPTOR;

ADRENERGIC SYSTEM; ARTICLE; BODY WEIGHT; CARDIAC PATIENT; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DISEASE MODEL; DIURETIC THERAPY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; HEART FAILURE; HORMONE RELEASE; HUMAN; HYPONATREMIA; KIDNEY TUBULE ABSORPTION; MOLECULAR MECHANICS; MORTALITY; NONHUMAN; OPTIMAL DRUG DOSE; PATHOGENESIS; PRESSORECEPTOR; PRIORITY JOURNAL; QUALITY OF LIFE; RECEPTOR AFFINITY; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REPEATED DRUG DOSE; SINGLE DRUG DOSE; SODIUM BLOOD LEVEL; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE; URINE VOLUME; WEIGHT REDUCTION;

ANIMALS; ARGININE VASOPRESSIN; CLINICAL TRIALS AS TOPIC; DIURETICS; HEART FAILURE; HUMANS; HYPONATREMIA; QUALITY OF LIFE; RECEPTORS, VASOPRESSIN;

EID: 69249220151     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-009-6180-9     Document Type: Article

References (59)

1. W Rosamond K Flegal K Furie, et al. 2008 American heart association statistics committee and stroke statistics subcommittee. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation 117 e25 146
2. DD Shin F Brandimarte L De Luca, et al. 2007 Review of current and investigational pharmacologic agents for acute heart failure syndromes Am J Cardiol 99 4A 23A
3. A Spital 1999 Diuretic-induced hyponatremia Am J Nephrol 19 447 52
4. A Ahmed A Husain TE Love, et al. 2006 Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods Eur Heart J 27 1431 9
5. DA Sica 2006 Sodium and water retention in heart failure and diuretic therapy: basic mechanisms Cleve Clin J Med 73 S2 7
6. A Goldberg H Hammerman S Petcherski, et al. 2006 Hyponatremia and long-term mortality in survivors of acute ST-elevation myocardial infarction Arch Intern Med 166 781 6
7. L De Luca L Klein JE Udelson, et al. 2005 Hyponatremia in patients with heart failure Am J Cardiol 96 19L 23L
8. CR Lee ML Watkins JH Patterson, et al. 2003 Vasopressin: a new target for the treatment of heart failure Am Heart J 146 9 18
9. Heart Failure Society of America 1999 HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction-pharmacological approaches J Card Fail 5 357 82
10. DA Sica 2005 Hyponatremia and heart failure-pathophysiology and implications Congest Heart Fail 11 274 7
11. S Ishikawa RW Schrier 2003 Pathophysiological roles of arginine vasopressin and aquaporin-2 in impaired water excretion Clin Endocrinol (Oxf) 58 1 17
12. FL Dunn TJ Brennan AE Nelson GL Robertson 1973 The role of blood osmolality and volume in regulating vasopressin secretion in the rat J Clin Invest 52 3212 9
13. Robertson GL, Athar S, Shelton RL. Osmotic control of vasopressin function. In: Robertson GL, editor. Disturbance in body fluid osmolality. Washington, DC: American Physiological Society; 1977. p. 251-306.
14. PH Baylis 1983 Posterior pituitary function in health and disease Clin Endocrinol Metab 12 747 70
15. J Penit M Faure S Jard 1983 Vasopressin and angiotensin II receptors in rat aortic smooth muscle cells in culture Am J Physiol 244 E72 82
16. S Neilsen TH Kwon BM Christensen D Promeneur J Frøkiaer D Marples 1999 Physiology and pathophysiology of renal aquaporins J Am Soc Nephrol 10 647 63
17. SR Goldsmith 1987 Vasopressin as vasopressor Am J Med 82 1213 9
18. AJG Riegger G Liebau 1982 The renin-angiotensin-aldosterone system, antidiuretic hormone and sympathetic nerve activity in an experimental model of congestive heart failure in the dog Clin Sci (Lond) 62 465 9
19. VL Szatalowicz PE Arnold C Chaimovitz D Bichet T Berl RW Schrier 1981 Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure N Engl J Med 305 263 6
20. W Pruszczynski A Vahanian R Ardaillou J Acar 1984 Role of antidiuretic hormone in impaired water excretion of patients with congestive heart failure J Clin Endocrinol Metab 58 599 605
21. GS Francis C Benedict DE Johnstone, et al. 1990 Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD) Circulation 82 1724 9
22. DG Bichet C Kortas B Mettauer, et al. 1986 Modulation of plasma and platelet vasopression by cardiac function in patients with heart failure Kidney Int 29 1188 96
23. RW Schrier W Abraham 1999 Hormones and hemodynamics in heart failure N Engl J Med 341 577 85
24. RW Schrier PY Martin 1998 Recent advances in the understanding of water metabolism in heart failure Adv Exp Med Biol 449 415 26
25. L Klein CM O'Connor JD Leimberger, et al. 2005 OPTIME-CHF Investigators. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study Circulation 111 2454 60
26. M Gheorghiade WA Gattis CM O'Connor, et al. 2004 Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized c JAMA 291 1963 71
27. WH Lee M Packer 1986 Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure Circulation 73 2 257 67
28. M Gheorghiade WT Abraham NM Albert, et al. 2007 OPTIMIZE-HF Investigators and Coordinators. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry Eur Heart J 28 980 8
29. LS Lilly VJ Dzau GH Williams L Rydstedt NK Hollenberg 1984 Hyponatremia in congestive heart failure: implications for neurohumoral activation and responses to orthostasis J Clin Endocrinol Metab 59 924 30
30. RM Oren 2005 Hyponatremia in congestive heart failure Am J Cardiol 95 2B 7B
31. The CONSENSUS Trial Study Group 1987 Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Surival Study (CONSENSUS) N Engl J Med 316 1429 35
32. The SOLVD Investigators 1991 Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure N Engl J Med 325 5 293 302
33. The SOLVD Investigators 1992 Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions N Engl J Med 327 10 685 91
34. A Nohria E Lewis LW Stevenson 2002 Medical management of advanced heart failure JAMA 287 628 40
35. BK Kramer F Schweda GAJ Riegger 1999 Diuretic treatment and diuretic resistance in heart failure Am J Med 106 90 6
36. A Greenberg 2000 Diuretic complications Am J Med Sci 319 10 24
37. M Burnier HR Brunner 1992 Neurohormonal consequences of diuretics in different cardiovascular syndromes Eur Heart J 13 28 33
38. A Sigurdsson K Swedberg 1995 Neurohormonal activation and congestive heart failure: today's experience with ACE inhibitors and rationale for their use Eur Heart J 16 65 72
39. M Sonnenblick Y Friedlander AJ Rosin 1993 Diuretic-induced severe hyponatremia. Review and analysis of 129 reported patients Chest 103 601 6
40. A Baglin JC Boulard T Hanslik J Prinseau 1995 Metabolic adverse reactions to diuretics Drug Saf 12 161 7
41. RH Sterns 1987 Severe symptomatic hyponatremia: treatment and outcome. A study of 64 cases Ann Intern Med 107 656 64
42. M Abramow E Cogan 1984 Clinical aspects and pathophysiology of diuretic-induced hyponatremia Adv Nephrol Necker Hosp 13 1 28
43. 2 antagonist in men J Pharmacol Exp Ther 272 546 51
44. 2 antagonist OPC-31260 in heart failure in the rat Am J Physiol 275 176 82
45. 2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats J Pharmacol Exp Ther 292 288 94
46. 2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind randomized trial Circulation 107 2690 6
47. MA Konstam M Gheorghiade JC Burnett Jr, et al. 2007 Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized with worsening heart failure: the EVEREST Outcome Trial JAMA 297 1319 31
48. M Gheorghiade MA Konstam JC Burnett Jr, et al. 2007 Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials JAMA 297 1332 43
49. 2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial J Am Coll Cardiol 52 1540 5
50. WT Abraham AA Shamshirsaz K McFann RM Oren RW Schrier 2006 Aquaretic effect of lixivaptan, an oral non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association Functional Class II and III chronic heart failure patients J Am Coll Cardiol 47 1615 21
51. CardioKine Inc. THE BALANCE study: treatment of hyponatremia based on Lixivaptan in NYHA class III/IV cardiac patient evaluation. http://www. clinicaltrials.gov. Accessed 23 March 2009.
52. 2-receptor antagonist, for hyponatremia N Engl J Med 355 2099 112
53. National Heart, Lung, and Blood Institute. Determining optimal dose and duration of diuretic treatment in people with acute heart failure (The DOSE-AHF Study). http://www.clinicaltrials.gov. Accessed 22 February 2009.
54. GS Francis RM Siegel SR Goldsmith, et al. 1985 Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohormonal axis Ann Intern Med 103 1 6
55. JE Udelson C Orlandi T O'Brien R Sequeira J Ouyang MA Konstam 2002 Vasopressin receptor blockade in patients with congestive heart failure: results from a placebo controlled, randomized study comparing the effects of tolvaptan, furosemide, and their combination J Am Coll Cardiol 39 156 Abstract
56. D Zeltser S Rosansky H van Rensburg JG Verbalis N Smith 2007 Conivaptan study group. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia Am J Nephrol 27 447 57
57. 2 vasopressin receptor antagonist, in patients with advanced heart failure Circulation 104 2417 23
58. SR Goldsmith U Elkayam WE Haught A Barve W He 2008 Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study J Card Fail 14 641 7
59. SR Goldsmith U Elkayam B McNutt Z Wang 2008 Combined effects of conivaptan and furosemide on urine output in patients with acute decompensated heart failure Crit Care Med 36 A61